Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to find a more objective and accurate way to assess the
efficacy of the treatment for neurogenic orthostatic hypotension. For this purpose, the
investigators will use an activity monitor to determine the amount of time patients spend in
the upright position (standing and walking; upright time) during 1 week of placebo (a pill
with no active ingredients) and 1 week of their regular medication for orthostatic
hypotension (midodrine or atomoxetine at their usual doses). Total upright time (i.e.
tolerance to standing and walking) will be compared between placebo and active treatment to
test the hypothesis that it can be used to assess the efficacy of the treatment for
orthostatic hypotension and whether this outcome is superior to the assessment of symptoms
using validated questionnaires.